{"id":"NCT01516424","sponsor":"Sumitomo Pharma (Suzhou) Co., Ltd.","briefTitle":"Efficiency Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone","officialTitle":"A Randomized, Double-blinded, Double-dummy, Parallel-controlled and Multicenter Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-02","primaryCompletion":"2013-02","completion":"2013-02","firstPosted":"2012-01-24","resultsPosted":"2018-11-26","lastUpdate":"2018-11-27"},"enrollment":267,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"Blonanserin","otherNames":["Lonasen"]},{"type":"DRUG","name":"Risperidone","otherNames":["Risperdal"]}],"arms":[{"label":"Blonanserin","type":"EXPERIMENTAL"},{"label":"Risperidone","type":"ACTIVE_COMPARATOR"}],"summary":"A Randomized, Double-blinded, Double-dummy, Parallel-controlled and Multicenter Clinical trial to Investigate Blonanserin in Treatment of Schizophrenia when compared with Risperidone","primaryOutcome":{"measure":"Change From Baseline in PANSS(Positive and Negative Syndrome Scale) Total Score at Week 8","timeFrame":"From baseline to the end of study„ÄÅweek 8(day 56)or before other antipsychotic taken.","effectByArm":[{"arm":"Blonanserin","deltaMin":-30.59,"sd":18.53},{"arm":"Risperidone","deltaMin":-33.56,"sd":16.89}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.05"},{"comp":"OG000 vs OG001","p":"<0.05"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":4},"locations":{"siteCount":16,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":130},"commonTop":["Serum prolactin increase","Extrapyramidal disorders","Excitement","constipation","Insomnia"]}}